SC
REGN icon

Stance Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Stance Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,849
Closed -$2.74M – 224
2024
Q4 		$2.74M Buy
+3,849
New +$3.23M 1.7% 30

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Stance Capital's REGN Position: Q1 2025 in Review

Stance Capital sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 3,849 shares — an estimated $2.74M sold.

Stance Capital first reported a position in REGN in Q4 2024 and held it in 1 quarter. The position peaked at $2.74M in Q4 2024. 1,291 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • Stance Capital reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Stance Capital sold 3,849 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $2.74M.
  • Stance Capital first reported a position in Regeneron Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Stance Capital's Regeneron Pharmaceuticals position peaked at $2.74M in Q4 2024.
  • 1,291 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Stance Capital's 13F filing for Q1 2025, filed 16 May 2025.